PT  - JOURNAL ARTICLE
AU  - Alexander, Lori
ED  - Barter, Philip
TI  - Final Results of the ILLUMINATE Trial
DP  - 2007  01
TA  - MD Conference Express
PG  - 14--15
VI  - 7
IP  - 7
4099  - http://mdc.sagepub.com/content/7/7/14.short
4100  - http://mdc.sagepub.com/content/7/7/14.full
AB  - The final results of the ILLUMINATE trial comparing the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib plus atorvastatin with atorvastatin alone in patients at high risk for cardiovascular disease showed that the rates of major cardiovascular events and all-cause mortality were higher with the addition of torcetrapib. The study had been prematurely terminated in December 2006 because of a significant excess of deaths and cardiovascular events in the group randomized to torcetrapib plus atorvastatin.